| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA5134023 | F | Antiviral activity against SARS-Cov-2 infected in african green monkey Vero E6 cells assessed as inhibition of viral replication pretreated with compound for 1 hr followed by viral infection for 2 hrs measured after 24 hrs post infection by qRt-PCR analysis | Severe acute respiratory syndrome coronavirus 2 | 2 | organism-based format | Scientific Literature | ||
| 2. | ALA5134025 | F | Antiviral activity against SARS-Cov-2 infected in african green monkey Vero E6 cells assessed as inhibition of viral replication pretreated with compound for 1 hr followed by viral infection for 2 hrs measured after 24 hrs post infection in presence of wallichins C by qRt-PCR analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | organism-based format | Scientific Literature | ||
| 3. | ALA5134026 | T | Cytotoxicity against African green monkey Vero E6 cells by CCK-8 assay | Chlorocebus sabaeus | 2 | cell-based format | Scientific Literature | ||
| 4. | ALA5134028 | T | Cytotoxicity against African green monkey Vero E6 cells in presence of wallichins C by CCK-8 assay | Chlorocebus sabaeus | 1 | cell-based format | Scientific Literature | ||
| 5. | ALA5134029 | T | Selectivity index, ratio for CC50 of African green monkey Vero E6 cells to EC50 for SARS-Cov-2 infected in african monkey Vero E6 cells | 2 | assay format | Scientific Literature | |||
| 6. | ALA5134031 | T | Selectivity index, ratio of CC50 for African green monkey Vero cells in presence of wallichins D to EC50 for SARS-Cov-2 infected in african green monkey Vero E6 cells assessed as inhibition of viral replication in presence of wallichins C | 1 | assay format | Scientific Literature | |||
| 7. | ALA5134032 | F | Antiviral activity against SARS-Cov-2 infected in human Calu-3 cells assessed as inhibition of viral replication pretreated with compound for 1 hr followed by viral infection for 2 hrs measured after 24 hrs post infection by qRt-PCR analysis | Severe acute respiratory syndrome coronavirus 2 | 2 | organism-based format | Scientific Literature | ||
| 8. | ALA5134034 | F | Antiviral activity against SARS-Cov-2 infected in human Calu-3 cells assessed as inhibition of viral replication pretreated with compound for 1 hr followed by viral infection for 2 hrs measured after 24 hrs post infection in presence of wallichins C by qRt-PCR analysis | Severe acute respiratory syndrome coronavirus 2 | 1 | organism-based format | Scientific Literature | ||
| 9. | ALA5134035 | T | Cytotoxicity against human Calu-3 cells by CCK-8 assay | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
| 10. | ALA5134037 | T | Cytotoxicity against human Calu-3 cells in presence of wallichins C by CCK-8 assay | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 11. | ALA5134038 | B | Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM by SPR assay | Severe acute respiratory syndrome coronavirus 2 | 3 | single protein format | Scientific Literature | ||
| 12. | ALA5134040 | B | Binding affinity to SARS-CoV-2 3CL protease at 1.875 to 50 uM in presence of wallichins C by SPR assay | Severe acute respiratory syndrome coronavirus 2 | 1 | single protein format | Scientific Literature | ||
| 13. | ALA5134041 | B | Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by substrate addition measured after 10 mins by FRET assay | Severe acute respiratory syndrome coronavirus 2 | 3 | single protein format | Scientific Literature | ||
| 14. | ALA5134043 | B | Inhibition of SARS-CoV-2 3CL protease using MCA-AVLQSGFR-Lys(Dnp)-Lys-NH2 as flurogenic substrate pre-incubated with compound for 10 mins followed by substrate addition measured after 10 mins in presence of wallichins C by FRET assay | Severe acute respiratory syndrome coronavirus 2 | 1 | single protein format | Scientific Literature | ||
| 15. | ALA5134044 | B | Binding affinity to TMPRSS2 (unknown origin) at 1.875 to 50 uM by SPR assay | Homo sapiens | 2 | single protein format | Scientific Literature | ||
| 16. | ALA5134045 | B | Binding affinity to cathepsin B (unknown origin) at 1.875 to 50 uM by SPR assay | Homo sapiens | 2 | single protein format | Scientific Literature | ||
| 17. | ALA5134046 | B | Binding affinity to SARS-CoV-2 full length Spike glycoprotein at 1.875 to 50 uM by SPR assay | Severe acute respiratory syndrome coronavirus 2 | 2 | single protein format | Scientific Literature | ||
| 18. | ALA5134047 | B | Binding affinity to ACE2 (unknown origin) at 1.875 to 50 uM by SPR assay | Homo sapiens | 2 | single protein format | Scientific Literature | ||
| 19. | ALA5134048 | B | Binding affinity to SARS-CoV-2 Spike glycoprotein receptor-binding domain at 1.875 to 50 uM by SPR assay | Severe acute respiratory syndrome coronavirus 2 | 2 | single protein format | Scientific Literature | ||
| 20. | ALA5134049 | F | Antiviral activity against SARS CoV-2 VSV-delG pseudotype infected in african green monkey Vero E6 at 100 uM measured after 15 hrs post infection relative to control | Severe acute respiratory syndrome coronavirus 2 | 2 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!